View on GitHub

This release contains updates to the current and draft versions of the database with FDA oncology approvals from June, July, and August 2025. The change log local to this repository has been removed and pointers now direct to news.moalmanac.org. Release notes will also continue to be available through this repository’s Releases.

Database content updates

Added entries:

  • (FDA) Datopotamab deruxtecan for the treatment of adult patients with locally advanced or metastatic EGFR mutated non-small cell lung cancer.
  • (FDA) Datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR+, HER2-negative breast cancer (in development version only).
  • (FDA) Pembrolizumab for the treatment of patients with head and neck squamous cell cancer with PD-L1 (CPS) >= 1 (in development version only).
  • (FDA) Sunvozertinib for the treatment of patients with locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations.
  • (FDA) Zongertinib for the treatment of adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations (in development version only).